11 June 2018

Under the name TopFit Impact Programme, Radboudumc, Radboud University, the University of Twente and Wageningen University & Research, join together in an impact programme aimed at preventing and reducing disease and the burden of disease.

Framework

Much progress has been made in recent years in understanding disease processes and the development of new treatment methods. At the same time, the realization that many diseases will remain incurable for the foreseeable future grows. Through smart integration of innovative technologies and knowledge about nutrition and health we can be one step ahead of disease and its burdens.

These integral solutions mean that there will be an ever more personal approach in healthcare. The payoff is a maximum increase in the quality of life of patients and the best perspective on affordable healthcare in an aging society. The goal of the TopFit programme is to contribute to controlling and limiting the cost of healthcare in the future, without making concessions to the quality of life of patients.

Impact

TopFit aspires to be a leading health impact programme on three levels: society & health, innovation & (regional) economy and science & technology. Therefore, the researchers work together with key partners in the east of the Netherlands.

During the summer of 2018 the programme will be further specified. After that, more information about TopFit will be available.

Contact

Are you interested in the TopFit Impact Programme? Do you want to be involved or do you have questions? Please contact Nathalie Bovy-vanderLugt.
 

Related news items


Jong KNCV organizes a Pitch competition for PhD candidates

13 August 2020

Are you a PhD candidate and would you like to win 500 euros with a pitch about your research? Young KNCV gives you that chance! During the KNCV Chemistry 2020 Evening on October 8th.

read more

Collective invasion induced by autocrine purinergic loop through connexin-43 hemichannels

13 August 2020

Peter Friedl and Paul Span show in Journal of Cell Biology that breastcancer cells release purines into the extracellular space via connexin-43 hemichannels to control collective invasion.

read more

TP53 allelic state is critical for diagnostic and prognostic precision in blood cancer

12 August 2020

An international study, in which Joop Jansen participated, shows that a double mutaton in TP53 gene deteriotes the prognosis of a rare form of blood cancer. If there is only one mutation or no mutation, then the prognosis is better.

read more

BCG vaccine is safe with no increased risk of COVID-19 symptoms says Mihai Netea

11 August 2020

The BCG vaccine has a general stimulatory effect on the immune system and is therefore effective against multiple infectious diseases - possibly also against COVID-19.

read more

650,000 Euro funding for research into the phasing out of medication for leukaemia patients

30 July 2020

With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.

read more

Increased role of patients after bowel cancer treatment

30 July 2020

Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.

read more